Buying a Pharmacy Business

Loan options

• SBA 7(a) Standard Loan

  Acquiring an independent retail or compounding pharmacy with an established prescription file, patient base, and documented cash flow; ideal for pharmacist-buyers seeking to finance the full acquisition including goodwill, equipment, and working capital in a single loan structure

• SBA 7(a) Small Loan

  Smaller independent pharmacy acquisitions or add-on purchases such as acquiring a prescription file from a closing pharmacy or a micro-location with limited hard assets; best when total deal consideration falls below $500,000

• SBA 504 Loan$5,500,000 combined (SBA debenture up to $5M plus bank portion) · 10- or 20-year fixed-rate debenture for the SBA portion; primarily used for fixed asset financing

  Pharmacy acquisitions where the buyer is also purchasing the real estate or making significant leasehold improvements to an owned facility; less commonly used for pure business acquisitions without a real property component

Eligibility

• The buyer must be a U.S. citizen or lawful permanent resident and must plan to actively manage or operate the acquired pharmacy, which for most lenders means holding or obtaining a pharmacist license or partnering with a licensed pharmacist in a management capacity
• The pharmacy being acquired must be a for-profit business operating in the United States with a demonstrable history of revenue and cash flow, typically evidenced by three years of tax returns and monthly prescription volume reports by payer
• The total deal size, including the purchase price, inventory at cost, and working capital, must fall within SBA loan limits, with a maximum SBA 7(a) loan amount of $5 million per borrower
• The buyer must inject a minimum of 10% equity into the transaction, though lenders may require 15–20% equity when the deal involves significant goodwill relative to hard assets, which is common when a large portion of the purchase price is attributed to the prescription file

Step by step

1. Engage an SBA Lender with Healthcare and Pharmacy Acquisition Experience2–4 weeks

   Not all SBA lenders are equipped to underwrite pharmacy acquisitions.

2. Execute a Letter of Intent and Engage Pharmacy-Specialized Advisors2–4 weeks

   Draft and negotiate a non-binding letter of intent covering the purchase price, deal structure including allocation between prescription file, inventory, equipment, and goodwill, any seller carry provisions, exclusivity period, and key closing conditions.

3. Complete Due Diligence on Financials, Compliance, and Payer Contracts30–60 days

   Conduct full due diligence covering the pharmacy's adjusted EBITDA with owner add-backs, prescription file analysis including active patient count and refill rate trends, PBM contract terms and DIR fee exposure, DEA registration status and change-of-ownership requirements, state pharmacy board license transferability, staff credentials and retention risk, inventory valuation, and accounts receivable aging by payer.

4. Finalize SBA Loan Application and Submit to Lender3–6 weeks

   Work with your SBA lender to complete the full loan application package, including the executed purchase agreement, business valuation, personal financial statements, three years of business tax returns, a business plan with pharmacy-specific financial projections, and documentation of the equity injection source.

5. Obtain DEA Change-of-Ownership Approval and State Board Clearance60–120 days, overlapping with financing steps

   Simultaneously with the SBA loan process, the buyer must apply for a new DEA registration under the acquiring entity.

Other financing

• SBA 7(a) Loan

  The most common financing vehicle for independent pharmacy acquisitions, SBA 7(a) loans cover up to $5M including goodwill, prescription file value, inventory, and working capital.

  • + Low down payment requirement of 10–15% makes ownership accessible for pharmacist-buyers with limited capital
  • + Prescription file and goodwill are eligible collateral, unlike most conventional business loans
  • − DEA change-of-ownership approval and state board transfer can delay funding and closing timelines significantly
  • − Lenders require clean PBM contract review and may discount value if DIR fee exposure is high
• Seller Financing (Seller Carry Note)6%–8% fixed, typically interest-only for 12 months then amortizing

  Pharmacy sellers frequently carry 10–20% of the purchase price as a subordinated note, especially where prescription file retention risk or payer contract uncertainty creates valuation gaps.

  • + Bridges valuation gaps created by PBM reimbursement uncertainty or earnout disagreements between buyer and seller
  • + Required by most SBA lenders as an equity injection substitute, reducing buyer's cash at close
  • − SBA standby requirements may restrict seller note repayment for 24 months, limiting seller liquidity
  • − Seller must remain creditworthy and willing to subordinate to SBA lender, which some retiring owners resist

Lender tips

• Seek out SBA Preferred Lender Program (PLP) lenders with documented experience in healthcare business acquisitions, specifically pharmacy or medical practice transactions, as they will process your application faster and underwrite pharmacy-specific cash flow more accurately than generalist SBA lenders
• Present a detailed prescription file analysis alongside your financial statements, including active patient count, average prescriptions per patient per year, 30-day refill rates, and payer mix breakdown — lenders who understand pharmacy will weight this data heavily in their underwriting and it demonstrates buyer sophistication
• Proactively address PBM reimbursement risk and DIR fee exposure in your business plan with a concrete strategy, whether that is diversifying into compounding, long-term care contracts, or specialty services, as lenders will flag reimbursement compression as a key risk and want to see that the buyer has a plan
• Structure the seller carry as a full standby note for the first 24 months if possible, as this satisfies SBA equity injection requirements while giving the new owner time to stabilize operations and patient volume before subordinated debt service begins

• Asset Purchase with Prescription File and Inventory Priced Separately70–80% of pharmacy transactions in the lower middle market use this structure as the primary deal framework.

  The dominant deal structure in independent pharmacy acquisitions. The buyer purchases specific business assets — primarily the prescription file, fixtures, equipment, and goodwill — while inventory is priced at cost at closing via a physical count.

  • + Buyer avoids inheriting undisclosed liabilities including PBM audit clawbacks or DEA compliance issues
  • + Prescription file and goodwill can be valued independently, giving sellers credit for a loyal, high-refill patient base
  • − DEA change-of-ownership registration and state pharmacy board approval must be completed before the buyer can legally dispense, creating a gap period
  • − PBM contracts often do not automatically transfer and require separate credentialing applications that can take 60–120 days
• SBA 7(a) Loan with Seller Carry NoteApproximately 60–70% of independent pharmacy acquisitions under $5M utilize SBA 7(a) financing as the primary debt instrument.

  The most common financing stack for independent pharmacy acquisitions under $5M in enterprise value. The buyer secures an SBA 7(a) loan — typically covering 70–80% of the purchase price — while the seller carries a subordinated note for 10–20% of the deal.

  • + Enables pharmacist-buyers without significant capital to acquire established practices with minimal equity out of pocket
  • + Seller carry signals confidence in the business to SBA lenders and reduces the financing gap in deals where bank appraisals fall short of asking price
  • − SBA underwriting requires 3 years of tax returns, a clean DEA and compliance history, and debt service coverage ratios that some marginally profitable pharmacies cannot meet
  • − Seller is exposed to default risk on the carry note if the buyer fails to retain the patient base or loses key PBM contracts post-close
• Earnout Tied to Prescription Volume and Patient File RetentionEarnout provisions appear in approximately 30–40% of independent pharmacy deals, most commonly as a supplement to SBA financing rather than a standalone structure.

  An earnout structure defers a portion of the purchase price — typically 10–25% — contingent on the pharmacy retaining a defined percentage of active patients and prescription volume over a 12–24 month period post-close.

  • + Bridges valuation gaps when buyers are skeptical about patient retention post-ownership-change, allowing sellers to earn full value if the business performs
  • + Incentivizes sellers to actively support the transition — introducing patients to the new owner and ensuring staff continuity during the earnout window
  • − Earnout disputes are common in pharmacy deals when prescription volume declines due to factors outside the seller's control, such as PBM reimbursement changes or competitor openings
  • − Requires robust post-close reporting systems and agreement on measurement methodology before signing — often a source of negotiation friction

Negotiation tips

• Separate the prescription file valuation from goodwill and equipment early in negotiations — prescription files in active pharmacies with strong 30-day refill rates (above 60%) command premium value and should be supported with dispensing data, not just revenue figures.
• Push for a 90–120 day due diligence period to allow time to review PBM contract change-of-ownership provisions and DIR fee reconciliation history — DIR fee clawbacks can materially reduce post-close cash flow and should be modeled into your purchase price, not discovered after signing.
• If structuring a seller carry note, negotiate for the seller to have skin in the game during transition: tie the note's payment commencement to the successful transfer of key PBM credentialing and DEA registration to the buyer's entity to ensure the seller remains motivated through the regulatory process.
• Include a rep and warranty in the asset purchase agreement requiring the seller to disclose any open CMS audits, PBM audit letters, or state board investigations — undisclosed compliance issues post-close can void preferred network status and devastate reimbursement rates overnight.

Financial Performance & Reimbursement Analysis

• Review 3 years of tax returns, P&L statements, and monthly revenue reports segmented by payer and drug category.critical

  Reveals true revenue mix and identifies dangerous concentration in low-margin payers or generics.

• Obtain a trailing 12-month DIR fee reconciliation report from each PBM relationship.critical

  DIR fees are retroactively clawed back and can reduce net reimbursement by 5–15%, distorting EBITDA.

• Recalculate adjusted EBITDA by normalizing owner compensation, perks, and non-recurring expenses.critical

  Owner-pharmacists frequently understate compensation, inflating apparent profitability for buyers.

• Analyze accounts receivable aging from third-party payers, Medicare Part D, and Medicaid.important

  Aged receivables over 90 days from government payers may indicate billing disputes or audit exposure.

Prescription File & Patient Base Integrity

• Request a prescription file report showing active patient count, 30-day refill rates, and top drug categories.critical

  Active refill volume is the primary value driver; declining counts signal patient attrition risk.

• Confirm the prescription file is owned by the business entity and not personally by the pharmacist-owner.critical

  Personally held prescription files may not transfer with an asset purchase, destroying core business value.

• Assess patient concentration risk by reviewing the top 50 patients by annual prescription spend.important

  Excessive concentration in a few high-spend patients creates attrition risk that can materially reduce revenue.

• Review any long-term care, hospice, or institutional facility contracts included in the prescription volume.important

  Recurring institutional contracts are highly valuable but may require renegotiation or approval upon ownership change.

DEA, Licensing & Regulatory Compliance

• Verify DEA registration is active, current, and review the full DEA inspection and audit history.critical

  DEA violations or open investigations can prevent license transfer and halt the acquisition entirely.

• Confirm state pharmacy board license is in good standing and assess change-of-ownership transfer requirements.critical

  Most states require board approval for ownership transfer, adding 30–90 days to the closing timeline.

• Review all PBM provider agreements for change-of-ownership provisions and preferred network eligibility requirements.critical

  PBM contracts may terminate automatically upon ownership change, eliminating reimbursement from major payers.

• Request CMS, Medicaid, and Part D audit history for the past 3 years including any repayment demands.important

  Unresolved government payer audits can result in recoupment claims that survive an asset purchase transaction.

Inventory & Physical Asset Valuation

• Commission an independent inventory count and confirm valuation methodology at cost, not retail pricing.critical

  Sellers may inflate inventory value using retail prices; buyers pay replacement cost, not dispensed value.

• Identify and exclude expired, controlled substance, or non-returnable inventory from the purchase price.important

  Expired or non-returnable drugs have zero value and should not be included in the inventory purchase price.

• Review pharmacy equipment condition including dispensing systems, compounding hoods, and refrigeration units.standard

  Equipment replacement costs can run $50,000–$200,000 and should be factored into purchase price negotiation.

• Review the facility lease for assignability, remaining term, renewal options, and landlord consent requirements.important

  A short lease with no renewal option creates operational risk and may limit ability to secure SBA financing.

Pharmacy-specific checks

• Request a payer concentration report showing what percentage of revenue comes from each PBM, Medicare Part D plan, or Medicaid managed care organization.
• Verify preferred network status with major PBMs including Express Scripts, CVS Caremark, and OptumRx, as loss of network access post-close eliminates covered patients.
• Confirm all long-term care, hospice, or employer group contracts include change-of-ownership provisions and are assignable to the buyer without renegotiation.
• Review any CMS, state Medicaid, or PBM audit findings from the prior three years and confirm all recoupments or corrective action plans are resolved before closing.
• Assess whether the pharmacy's NPI, NCPDP provider number, and Medicare/Medicaid enrollment can be transferred or require a new enrollment with potential gaps in billing eligibility.

Red flags

• DEA registration has open violations, warning letters, or controlled substance discrepancy reports within the past 5 years
• PBM contracts contain automatic termination clauses triggered by ownership change, eliminating reimbursement access post-close
• Active state board investigation or disciplinary proceeding against the pharmacy license or the owner-pharmacist
• Seller is the sole licensed pharmacist with no staff pharmacist capable of operating the pharmacy independently
• Prescription file active patient count has declined more than 10% over the trailing 24 months with no clear explanation

What the LOI covers

• Parties and Transaction Overview

  Identifies the buyer and seller, the legal entity being acquired, the pharmacy's operating name, DEA registration number, and state pharmacy board license number.

• Purchase Price and Asset Allocation

  Defines the total purchase price and breaks it into its component parts: the prescription file value, tangible assets (fixtures, equipment, technology systems), goodwill, and a separately priced inventory component.

• Earnout Provision for Prescription File Retention

  Establishes a contingent payment tied to the retention of prescription volume, active patient count, or revenue from the acquired prescription file over a defined post-closing period, typically 12 to 24 months.

• Due Diligence Period and Access

  Defines the length of the due diligence period, what records and access the buyer is entitled to review, and the confidentiality obligations that govern information shared during this period.

• Regulatory Approvals and DEA Transfer Provisions

  Addresses the regulatory conditions that must be satisfied before closing, including new DEA registration for the buyer, state pharmacy board change-of-ownership approval, and PBM credentialing.

• Financing Contingency and SBA Loan Provisions

  States whether the offer is contingent on the buyer obtaining financing, identifies the financing source — typically an SBA 7(a) loan — and establishes the timeline for lender approval, commitment letter delivery, and any seller carry component.

Terms to negotiate

• DIR Fee and PBM Reimbursement Risk Allocation

  Direct and Indirect Remuneration fees are reconciled months after prescription fills and can materially reduce net pharmacy revenue.

• Inventory Pricing and Count Methodology

  Inventory is almost always priced separately in pharmacy asset purchases, but the LOI must define what 'cost' means, who conducts the count, and what happens to near-expired or slow-moving products.

• PBM Preferred Network Continuity Contingency

  Losing preferred network status with a major PBM post-acquisition can immediately reduce patient volume and reimbursement rates.

• Earnout Baseline Measurement Period and Exclusions

  Earnout provisions tied to prescription file retention are only as good as the baseline they are measured against.

Target profile

• Established active patient base with 30-day refill rates above 60% and low trailing-12-month patient churn
• Clean DEA registration and state pharmacy board compliance history with no pending investigations or audit findings
• Mix of retail and specialty or compounding revenue that reduces overconcentration in low-margin generic prescriptions
• Licensed pharmacist or lead technician willing to remain post-close, reducing transition risk and ensuring operational continuity

Platform and add-on criteria

• Revenue of $2M–$5M with 10%+ EBITDAPlatform

  Sufficient cash flow to support SBA or institutional financing, fund integration costs, and sustain operations during the ownership transition without requiring immediate operational overhaul.

• Specialty, compounding, or LTC contract revenuePlatform

  Non-PBM revenue streams such as compounding, long-term care, or hospice contracts provide margin insulation and a differentiated service base to build the platform identity around.

• Licensed pharmacist willing to remain post-closePlatform

  A retained, credentialed pharmacist ensures DEA and state board continuity, reduces patient attrition risk, and provides operational stability during platform buildout and add-on integrations.

• Clean DEA and state board compliance recordPlatform

  No outstanding violations, audit findings, or payer credentialing issues that would complicate change-of-ownership approvals, delay licensing transfers, or introduce liability into the platform.

Acquisition sequence

1. Anchor Acquisition: Establish the PlatformOperational stability, pharmacist retention, and SBA financing execution

   Identify and acquire a single well-run independent pharmacy with $2M–$4M in revenue, stable EBITDA margins of 10–15%, and a licensed pharmacist willing to remain post-close.

2. Build the Back Office Before the Second AcquisitionCentralized systems, compliance infrastructure, and multi-location reporting capability

   Before acquiring a second location, invest in centralized infrastructure: a pharmacy management system capable of multi-location reporting, a standardized billing and accounts receivable process for third-party payer reconciliation, and a compliance framework that covers DEA requirements and state board obligations across multiple licenses.

3. Second and Third Acquisitions: Geographic ClusteringGeographic clustering, service line diversification, and earnout-structured deal terms

   Target acquisitions within a defined geographic cluster — ideally within a 30–60 mile radius of your anchor location.

4. Scale Specialty and Compounding Across the PlatformSpecialty and compounding expansion, USP compliance, higher-margin revenue diversification

   Once you have three or more locations operating under centralized infrastructure, systematically add or expand specialty and compounding capabilities platform-wide.

Value creation levers

• Centralized Back-Office and G&A Rationalization

  Consolidating billing, HR, compliance monitoring, and purchasing across multiple pharmacy locations eliminates duplicative overhead.

• Specialty and Compounding Revenue Integration

  Adding specialty dispensing or compounding capabilities to acquired retail-only pharmacies increases blended gross margins and reduces dependence on PBM reimbursement.

• Wholesale Purchasing Leverage

  Aggregating prescription volume across multiple locations unlocks better pricing from primary wholesalers such as McKesson, Cardinal Health, or AmerisourceBergen.

• Pharmacist Staffing Optimization

  A multi-location platform can deploy licensed pharmacists more efficiently across locations, use float pharmacists to cover peak volume periods, and recruit more competitively against single-location independents by offering career progression and schedule flexibility.

Day one

• Confirm the DEA change-of-ownership application has been submitted and interim dispensing authorization is in place per DEA guidance.
• Notify all PBM networks of the ownership change and submit credentialing documentation to avoid reimbursement interruption or claim rejections.
• Introduce yourself to lead pharmacists and technicians, reaffirm employment terms, and confirm all staff licenses are current with the state board.
• Conduct a physical inventory count and reconcile against the seller's pre-close count to finalize inventory purchase price at cost.
• Communicate with front-line staff and, where appropriate, key patients to establish continuity of care and confidence in the transition.

Regulatory and Licensing Stabilization (Days 1–30)

• File DEA Form 224 or change-of-ownership documentation immediately at close and maintain copies of interim authorization for compliance review.
• Contact each state board of pharmacy to initiate license transfer, update authorized pharmacist-in-charge designation, and fulfill any inspection requirements.
• Audit all active PBM contracts for change-of-ownership provisions, preferred network eligibility requirements, and DIR fee clauses before submitting credentialing paperwork.

Operations and Staff Integration (Days 31–90)

• Hold one-on-one meetings with each licensed pharmacist to discuss role expectations, compensation structure, and any retention incentive agreements negotiated at close.
• Evaluate the existing pharmacy management system and either integrate with acquirer's platform or stabilize current software to avoid prescription file disruption.
• Pull weekly prescription volume and refill rate reports by drug category and payer to monitor patient retention against projections.

Revenue Optimization and Growth (Days 91–365)

• Review all PBM contract reimbursement rates against current MAC pricing benchmarks and renegotiate or exit networks with negative spread prescriptions.
• Identify and pursue long-term care facility or hospice partnerships in the local market to add contracted institutional prescription volume.
• Assess compounding lab certification status, equipment, and USP 797/800 compliance if compounding is part of the acquired pharmacy's revenue mix.

Pitfalls

• Reimbursement Interruption from Delayed PBM Credentialing

  Failing to notify PBM networks at close causes claim rejections and cash flow gaps. Submit credentialing packets on day one and track each network's credentialing timeline proactively.

• Losing the Licensed Pharmacist-in-Charge

  If the departing owner was the pharmacist-in-charge, operations can halt without a licensed replacement. Identify and designate a new PIC before close, not after.

• Underestimating Patient Attrition During Transition

  Patients loyal to the prior owner may transfer prescriptions elsewhere if communication is poor. A proactive patient communication plan in the first 30 days is essential to file retention.

• Ignoring DIR Fee Exposure and PBM Reimbursement Trendscritical

  Buyers often accept historical revenue at face value without modeling DIR fee clawbacks. These retroactive deductions can slash net reimbursement 10–20%, making a profitable pharmacy unprofitable post-close.

• Failing to Audit Prescription File Quality Before Closingcritical

  The prescription file is the pharmacy's core asset, but buyers often overpay by relying on total script count rather than analyzing active patients, 30-day refill rates, and drug category mix.

• Underestimating DEA and State Board Transfer Complexitycritical

  Buyers frequently assume licensing transfers quickly. DEA change-of-ownership registration and state pharmacy board approval often take 60–120 days, delaying close and creating operational gaps.

• Overlooking PBM Contract Change-of-Ownership Provisionsmajor

  Many PBM agreements allow termination or renegotiation upon ownership change. Losing preferred network status post-close can eliminate a significant portion of covered prescription volume overnight.

• Misjudging Staff Retention Risk After Ownership Transitionmajor

  Independent pharmacies often rely on one or two licensed pharmacists. If the owner-pharmacist departs without a retention plan, operations can halt and patients may transfer to competitors immediately.

• Accepting Seller's EBITDA Without Normalizing Owner Compensationmajor

  Pharmacy owners frequently underreport compensation or run personal expenses through the business. Buyers who skip recast financials overpay by applying a multiple to inflated earnings. How to avoid it: Require three years of tax returns and P&Ls.

Warning signs

• Seller is unable to produce a clean prescription file report with active patient counts and 30-day refill rates by payer
• DEA registration or state pharmacy board license has any open investigations, conditions, or recent audit findings
• More than 60% of prescription revenue flows through a single PBM network or preferred pharmacy contract
• Prescription volume or active patient count has declined for two or more consecutive years without a clear explanation
• The selling pharmacist holds the DEA registration personally and has no succession plan or licensed staff capable of assuming operations

Phase 1: Financial Documentation and Normalization (Months 1–4)

• Compile 3 years of tax returns, P&L statements, and monthly revenue reportshigh

  Gather federal tax returns, internally prepared P&Ls, and monthly revenue breakdowns segmented by payer type (Medicare Part D, Medicaid, commercial PBMs, cash) and drug category (brand, generic, specialty, compounded).

• Prepare a trailing 12-month and 36-month prescription volume trend reporthigh

  Export prescription count data from your pharmacy management system (PioneerRx, QS/1, Liberty, etc.) showing total prescriptions dispensed, active patient count, and 30-day refill rate trends over the past three years.

• Document and quantify DIR fee exposure and net reimbursement by PBMhigh

  Pull DIR fee recoupments from each PBM reconciliation report for the past two years and calculate your true net reimbursement per prescription after DIR adjustments.

Phase 2: Prescription File and Patient Base Preparation (Months 3–6)

• Generate a clean prescription file report with active patient count and refill metricshigh

  Produce a detailed prescription file report from your pharmacy management system showing total active patients (filled at least one prescription in the past 12 months), average prescriptions per patient per year, top 20 drug categories by volume, and 30-day refill adherence rates.

• Identify and document specialty, compounding, or LTC contract revenue separatelyhigh

  Isolate revenue from compounding services, long-term care facility contracts, hospice accounts, or specialty drug dispensing and document it separately from standard retail PBM revenue.

• Audit patient retention risk tied to owner-patient relationshipshigh

  Honestly assess how many of your most loyal patients have a strong personal relationship with you as the owner-pharmacist rather than with your staff or location.

Phase 3: Regulatory, Licensing, and Compliance Preparation (Months 4–8)

• Confirm DEA registration is current and review change-of-ownership transfer requirementshigh

  Verify your DEA registration is active, fully paid, and free of any pending investigations or consent agreements.

• Confirm state pharmacy board license is current and assess transferabilityhigh

  Contact your state board of pharmacy to confirm your pharmacy permit is current, in good standing, and to understand the new owner application and inspection process required in your state.

• Compile and review all PBM contracts for change-of-ownership provisionshigh

  Pull every active PBM provider agreement — Medicare Part D networks, Medicaid managed care contracts, commercial PBM agreements — and review the change-of-ownership, assignment, and termination clauses in each.

Phase 4: Operational Documentation and Asset Preparation (Months 6–10)

• Conduct a full pharmacy inventory count and document valuation methodologymedium

  Perform a physical inventory count of all drug stock and document your valuation methodology — most pharmacy transactions price inventory at cost (acquisition cost) and add it on top of the enterprise value at closing.

• Review your pharmacy lease for assignability and remaining termhigh

  Pull your commercial lease and review the assignment, sublease, and change-of-ownership clauses. Buyers — and SBA lenders — require a lease with sufficient remaining term, typically at least 3–5 years remaining or renewable, to justify the acquisition.

• Document vendor relationships, wholesaler contracts, and generic purchasing programsmedium

  Compile your primary drug wholesaler agreement, any generic purchasing programs (e.g., through PSAO or buying group membership), and preferred vendor contracts for durable medical equipment or compounding supplies.

Quick wins before a sale

• Pull your active patient count and 30-day refill rate report from your pharmacy management system today — this single metric will drive more of your valuation conversation than almost anything else, and knowing it before buyer conversations begin puts you in control
• Call your DEA Diversion Field Office to confirm your registration is current and ask about the change-of-ownership process in your region — most pharmacy owners are surprised to learn this process requires a new registration for the buyer, not a transfer of yours
• Log into your PBM portals for your top three payers and pull the last 12 months of DIR fee recoupment data — buyers will request this during due diligence and presenting it proactively signals transparency that builds buyer confidence
• Ask your commercial landlord informally whether they would consent to a lease assignment or extension — a short lease or a hostile landlord is one of the fastest deal-killers in pharmacy acquisitions, and knowing your position early gives you time to renegotiate

Questions to ask a broker

• How many independent pharmacy transactions have you closed in the last three years, and what was the average deal size?

  Pharmacy deals require specialized knowledge of DEA transfers, PBM contracts, and prescription file valuation. Generic business broker experience is insufficient.

• How do you value a pharmacy's prescription file, and do you account for DIR fee exposure and payer mix when calculating EBITDA?

  Prescription file value and DIR fee liability are the two most misunderstood drivers of pharmacy valuation. A weak answer signals inexperience.

• How do you vet buyers for pharmacist licensure, SBA eligibility, and ability to obtain DEA registration before accepting an offer?

  Unqualified buyers waste months and expose sellers to confidentiality risk. Pre-qualification is essential in a licensed, regulated industry.

Broker red flags

• Broker cannot explain DIR fees, PBM contract change-of-ownership clauses, or how prescription file value is calculated separately from business EBITDA.
• Broker has no healthcare or pharmacy transaction references and positions general retail business experience as equivalent expertise.
• Broker skips buyer pre-qualification for pharmacist licensure and DEA eligibility, creating pipeline risk with unqualified offers.